key: cord-0828119-t7fjn2no
authors: Rubenstein, Robyn N.; Stern, Carrie S.; Plotsker, Ethan L.; Haglich, Kathryn; Tadros, Audree B.; Mehrara, Babak J.; Matros, Evan; Nelson, Jonas A.
title: Effects of COVID‐19 on mastectomy and breast reconstruction rates: A national surgical sample
date: 2022-04-12
journal: J Surg Oncol
DOI: 10.1002/jso.26889
sha: 4209f3f1ca932c2463d870ed2216c7fff59df625
doc_id: 828119
cord_uid: t7fjn2no

BACKGROUND: The COVID‐19 pandemic profoundly impacted breast cancer treatment in 2020. Guidelines initially halted elective procedures, subsequently encouraging less invasive surgeries and restricting breast reconstruction options. We examined the effects of COVID‐19 on oncologic breast surgery and reconstruction rates during the first year of the pandemic. METHODS: Using the National Surgical Quality Improvement Program, we performed an observational examination of female surgical breast cancer patients from 2017 to 2020. We analyzed annual rates of lumpectomy, mastectomy (unilateral/contralateral prophylactic/bilateral prophylactic), and breast reconstruction (alloplastic/autologous) and compared 2019 and 2020 reconstruction cohorts to evaluate the effect of COVID‐19. RESULTS: From 2017 to 2020, 175 949 patients underwent lumpectomy or mastectomy with or without reconstruction. From 2019 to 2020, patient volume declined by 10.7%, unilateral mastectomy rates increased (70.5% to 71.9%, p = 0.003), and contralateral prophylactic mastectomy rates decreased. While overall reconstruction rates were unchanged, tissue expander reconstruction increased (64.0% to 68.4%, p < 0.001) and direct‐to‐implant and autologous reconstruction decreased. Outpatient alloplastic reconstruction increased (65.7% to 73.8%, p < 0.0001), and length of hospital stay decreased for all reconstruction patients (p < 0.0001). CONCLUSIONS: In 2020, there was a nearly 11% decline in breast cancer surgeries, comparable mastectomy and reconstruction rates, increased use of outpatient alloplastic reconstruction, and significantly reduced in‐hospital time across all reconstruction types.

The rise of the COVID-19 pandemic in 2020 caused unprecedented disruption in the delivery of surgical care for women with breast cancer, who constitute 14.8% of all new cancer cases in the United States. 1 Table S1 ). 4 Breast surgeons were encouraged to use breast-conserving therapy (BCT) whenever appropriate, pending the availability of radiation services. Early on, definitive mastectomy with or without reconstruction was recommended to be deferred, if possible. 4 Surgeons were instructed to delay operative management whenever clinically appropriate. 5 Neoadjuvant hormonal therapy and/or chemotherapy were considered safe methods of delaying surgery for eligible breast cancer patients.

As COVID-19 rates surged, breast cancer treatment guidelines were refined frequently, based on geographic and institutional COVID-19 burden. [5] [6] [7] While hospital resources and staff were limited in the acute stage of the pandemic, a Special Communication on the treatment of breast cancer recommended that eligible patients continue undergoing BCT rather than mastectomy and that patients requiring mastectomy could undergo reconstruction if resources allowed. 8 Notably, the COVID-19 Pandemic Breast Cancer Consortium guidelines limited breast reconstruction to alloplastic only, deferring autologous reconstruction. 8 The pandemic remained at different phases across the United States, and as each region slowly recovered from the first wave, a priority classification system was introduced for triaging breast cancer surgery based on the acuity of the patient's condition, survival likelihood, and availability of institution-specific resources (see Tables S2 and S3 ). 9 The guidelines continued to encourage less invasive procedures, outpatient recovery, contralateral prophylactic mastectomy (CPM) only for patients at high risk of contralateral breast cancer, and alloplastic reconstruction rather than autologous to reduce complication risks, inpatient stays, and patient exposure to COVID-19. 10 While the ACS discouraged completion of delayed reconstruction in patients who previously underwent mastectomy pre-pandemic, they did not formally make recommendations regarding the appropriateness of delaying reconstruction for patients undergoing mastectomy during the pandemic. 8 They reinforced the recommendation that physicians treat patients safely but promptly to prevent "backlogging" and extreme delays in the surgical care of breast cancer patients. 11 The ACS guidelines eventually permitted autologous reconstruction, depending on the phase of the pandemic, geographic location, and available resources at the treating institution. 12 Little is known of the effect these changes to breast cancer treatment guidelines had on lumpectomy, mastectomy (unilateral, contralateral prophylactic, bilateral prophylactic), and breast reconstruction (alloplastic and autologous) rates. The aim of this study was to examine how rates of oncologic breast surgery and breast reconstruction changed in 2020 due to the COVID-19 pandemic. A secondary aim was to compare basic patient demographics, surgical details, and hospitalization between the 2019 and 2020 alloplastic and autologous breast reconstruction cohorts to more closely evaluate the effects of COVID-19. We hypothesized that from 2019 to 2020 (1) the proportion of lumpectomy versus mastectomy procedures increased, as lumpectomy is an outpatient procedure, and (2) the proportion of alloplastic versus autologous reconstruction increased, as alloplastic reconstruction uses fewer hospital resources.

We used data abstracted from the ACS' National Surgical Quality Improvement Program (NSQIP) to perform an observational longitudinal analysis of female patients (≥18 years of age) who underwent lumpectomy or mastectomy from 2017 to 2020. NSQIP is an outcomes-based database that reports 30-day morbidity and mortality outcomes for all major inpatient and outpatient surgical procedures. 13 We used CPT codes for lumpectomy and mastectomy with and without reconstruction to filter the NSQIP data and From 2017 to 2020, lumpectomy rates decreased from 63.8% to 61.6%, while mastectomy rates increased from 36.2% to 38.4% (see Figure S1 ). There was a subtle variability in the annual rates per mastectomy type (Table 1 Overall immediate alloplastic (DTI and TE) and autologous breast reconstruction rates decreased from 2017 to 2019 (48.6% to 46.6%) but remained stable from 2019 to 2020 (Table 1 and Figure 2 ). Alloplastic reconstruction rates were higher than autologous reconstruction throughout the study period (Table 1 and Figure 2 ).

Alloplastic reconstruction rates decreased from 2017 to 2019 (87.2% to 84.8%) while autologous reconstruction increased (12.8% to 15.2%); however, there was a reversal in these trends from 2019 to 2020, with an increase in alloplastic reconstruction (84.8% to 86.6%) and decrease in autologous reconstruction (15.2% to 13.4%).

When distinguishing types of alloplastic reconstruction, Table 1 and When comparing 2019 with 2020, there was an increase in UM rates (70.5% to 71.9%) and a slight decrease in CPM (26.7% to 25.7%) and BPM (2.8% to 2.4%) (p = 0.003) rates (Table 2 ). There was no difference in overall immediate breast reconstruction rates between 2019 and 2020 (46.6% to 46.7%, p = 0.859) ( Table 2 ), but in 2020 there was a significant increase in alloplastic reconstruction (84.8% to 86.6%) and a decrease in autologous reconstruction (15.2% to 13.4%) (p = 0.001). Stratifying by method of alloplastic reconstruction, Table 2 and Figure 3 show an increase in TE reconstruction (64.0% to 68.4%) and a decrease in DTI reconstruction (20.7% to 18.2%) (p < 0.001).

When we compared the distribution of reconstruction procedures by mastectomy type in 2019 versus 2020 (Table 3) , there was a significant increase in the use of alloplastic reconstruction in patients with UM (83.2% to 86.2%, p < 0.0001), no difference in patients with CPM (87.6% to 87.9%, p = 0.714), and minimal difference in patients with BPM (82.1% to 81.4%, p = 0.847). When distinguishing between types of alloplastic reconstruction (Figure 4) , there was a significant increase in TE reconstruction (61.4% to 67.6%) and a decrease in DTI (21.8% to 18.6%) in patients with UM (p < 0.0001). In the CPM cohort, TE reconstruction increased and DTI and autologous reconstruction decreased, but these were not statistically significant (p = 0.189). In the BPM cohort, TE reconstruction decreased and DTI and autologous reconstruction increased, but these changes were not statistically significant either (p = 0.839).

When we compared 2019 versus 2020 basic demographic and clinical variables for alloplastic reconstruction patients (see Table S4 ), we noted minimal differences in age distribution and small differ- patients with hospitalization of 0 days increased from 9.6% to 25.9%, while the proportion of patients with hospitalization of 1 day decreased from 70.7% to 61.2% and decreased from 14.5% to 9.2% for patients hospitalized for 2 days (p < 0.0001).

When we compared 2019 versus 2020 basic patient variables for autologous reconstruction patients (see Table S5 ), we noted no Despite the push toward less invasive procedures, our data demonstrate a decrease in lumpectomy rates and an increase in mastectomy rates. The slight increase in mastectomy rates may have been influenced by limited resources for radiation therapy or efforts to mitigate exposure to patients through multiple radiation therapy sessions. 4 In addition, fewer patients may have been candidates for lumpectomy, as many cancers were detected by physical findings rather than routine imaging surveillance due to barriers in screening during the COVID-19 pandemic. However, the pre-pandemic limiting surgery to breasts with an oncologic diagnosis to reduce operative times and postoperative complication risk. 16, 17 In accordance with ACS guidelines, 10 we noted an increase in UM as compared with CPM and BPM; however, while this was statistically significant, it is unclear whether this increase is clinically profound, as our results do not suggest a drastic change in practice patterns. Rates of BPM remained low from 2019 to 2020, with a very slight decrease in the use of BPM (2.8% to 2.4%), suggesting that practices in BPM also did not change drastically due to the pandemic or ACS guidelines. 4, 9 During the course of the COVID-19 pandemic and its impact at F I G U R E 2 Trends in mastectomy rates by type, immediate breast reconstruction rates, and autologous versus alloplastic (tissue expander, direct-to-implant) reconstruction rates (2017-2020). BPM, bilateral prophylactic mastectomy; CPM, contralateral prophylactic mastectomy; DTI, direct-to-implant; TE, tissue expander; UM, unilateral mastectomy.

Delayed breast reconstruction was not examined in this study;

however, it must be noted that pre-pandemic, delayed reconstruction was shown to be beneficial in certain high-risk patients, even demonstrating lower complication rates and similar patient-reported outcomes (PROs) as immediate reconstruction. 22 (Figure 4) , reinforcing the concept that mastectomy patterns influence reconstruction patterns, even during the pandemic. 19 The most notable difference between the 2019 and 2020

alloplastic reconstruction cohorts was a large increase in outpatient procedures and a decrease in hospital length of stay for the remaining inpatients (see Table S4 ). The most notable difference between the 2019 and 2020 autologous reconstruction cohorts was a decrease in hospital length of stay (see Table S5 ). To reduce COVID-19 exposure risk and decrease hospital burden, multiple institutions implemented protocols to shorten the length of stay and promote same-day discharge in breast reconstruction patients whenever possible, sometimes using modified enhanced recovery after surgery pathways or increased regional anesthesia. 12 Additionally, as NSQIP examines individual surgical cases rather than following each patient's care long term, we excluded delayed reconstruction trends from our study, as the interpretation of trends in delayed reconstruction during the pandemic is less straightforward than trends in immediate reconstruction. Despite these limitations in mind, our findings provide insight into possible areas for future research with institutional or additional epidemiologic data sets.

Breast surgery volume declined by nearly 11% in 2020, the first year of the COVID-19 pandemic. While mastectomy and breast reconstruction rates were similar, alloplastic reconstruction was used more frequently and more commonly as an outpatient procedure.

Across all forms of reconstruction, in-hospital time significantly decreased. As the severity of the pandemic fluctuates, the effects of COVID-19 will likely continue to influence breast surgery and reconstruction practice patterns.

This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748, which supports Memorial Sloan

Kettering Cancer Center's research infrastructure.

The authors declare no conflicts of interest.

The data that support the findings of this study are provided by ACS-NSQIP and are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Jonas A. Nelson http://orcid.org/0000-0003-0329-4422

Cancer Stat Facts: Female Breast cancer

WHO declares COVID-19 a pandemic

COVID-19: Recommendations for Management of Elective Surgical Procedures

COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures

COVID-19: Elective Case Triage Guidelines for Surgical Care

Elective Case Triage Guidelines for Surgical Care: Breast Cancer Surgery

Association of periOperative Registered Nurses. American Hospital Association. Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic. 2020. Accessed

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium

ACS Guidelines for Triage and Management of Elective Cancer Surgery Cases During the Acute and Recovery Phases of Coronavirus Disease 2019 (COVID-19) Pandemic. 2020

COVID-19 Pandemic Breast Cancer Consortium. COVID-19 Pandemic Breast Cancer Consortium's Considerations for Re-entry

American College of Surgeons. American College of Surgeons Recommendations Concerning Surgery Amid the COVID-19

Breast reconstruction during the COVID-19 pandemic: a systematic review

American College of Surgeons. ACS National Surgical Quality Improvement Program

ACS NSQIP: History. Accessed

Time to treatment initiation for breast cancer during the 2020 COVID-19 pandemic

Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?

Freitas Junior R. Breast reconstruction and coronavirus pandemic

A paradigm shift in U.S. Breast reconstruction: increasing implant rates

A paradigm shift in U.S. breast reconstruction: Part 2. The influence of changing mastectomy patterns on reconstructive rate and method

Breast reconstruction and the COVID-19 pandemic: a viewpoint

Guidelines for breast reconstruction during the COVID-19 pandemic: are we considering enough evidence?

Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study

Comparison of wound complications after immediate, delayed, and secondary breast reconstruction procedures

Outcomes of immediate versus delayed breast reconstruction: results of a multicenter prospective study

Breast reconstruction in a coronavirus disease 2019 hub

COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic

High-efficiency same-day approach to breast reconstruction during the COVID-19 crisis

Breast surgery in the time of global pandemic: benefits of same-day surgery for breast cancer patients undergoing mastectomy with immediate reconstruction during COVID-19

Considerations for performing immediate breast reconstruction during the COVID-19 pandemic

Treatment protocol to allow reconstructive breast surgery during COVID-19 pandemic

COVID-19 microsurgical breast reconstruction national practise survey: a survey of BAPRAS members and proposal of COVID-19 specific perioperative and ERAS pathways

Resuming autologous free tissue transfer for breast reconstruction in the COVID-19 era

Breast reconstruction and the COVID-19 pandemic: adapting practice

The feasibility and safety of immediate breast reconstruction in the COVID-19 era

Restitution of the NHS breast reconstruction service during the recovery phase of the Covid 19 pandemic

Autologous breast reconstruction versus implant-based reconstruction: how do long-term costs and health care use compare?

Autologous versus implant-based breast reconstruction: a systematic review and meta-analysis of Breast-Q patient-reported outcomes

Direct-toimplant breast reconstruction: an analysis of 1612 cases from the ACS-NSQIP surgical outcomes database

Impact of transitioning to same day discharge following immediate prosthetic breast reconstruction during the COVID-19 pandemic. Abstract Presentation presented at Northeastern Society of Plastic Surgeons

Effects of COVID-19 on mastectomy and breast reconstruction rates: a national surgical sample